TRANSVAC-DS – Towards a sustainable European vaccine infrastruture
GenIbet is participating in “TRANSVAC-DS – Towards a sustainable European vaccine infrastructure”, a European vaccine research and development (R&D) infrastructure project coordinated by the European Vaccine Initiative (EVI) and dedicated to accelerating the development of safe, effective and affordable vaccines.
Scientist developing vaccine candidates face a number of different challenges – scientific, technical, regulatory and financial – which require a combination of knowledge, skills and technical capacities which are unlikely to be available at a single organization. By bringing together 25 partners within the European vaccine development landscape, with different backgrounds and capacities, TRANSVAC-DS aims to enable the access to innovative R&D services, technical training and state-of-the-art manufacturing facilities and facilitate the development of safe, effective and affordable vaccines.
GenIbet main role in this project is to provide access to GMP manufacturing services, on a pay-per-service basis.
If you are a researcher with good preliminary results, needing support to further develop vaccine candidates, apply for TRANSVAC2 Vaccine Development Services: Open call until April 15th, 2021